Posted by Michael Wonder on 16 Jul 2024
ICER publishes final evidence report on treatment for chronic obstructive pulmonary disease
16 July 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ensifentrine added to maintenance therapy compared to maintenance therapy alone; ICER calculated a health-benefit price benchmark (HBPB) for ensifentrine between $7,500 - $12,700/year, and the therapy is priced at $35,400/year.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of ensifentrine (Ohtuvayre, Verona Pharma) for the treatment of chronic obstructive pulmonary disease.
